AG490 inhibits NFATc1 expression and STAT3 activation during RANKL induced osteoclastogenesis

Biochemical and Biophysical Research Communications

Volumn 435, Issue 4, 2013, Pages 533-539

  Li, Chang hong ^a   Zhao, Jin xia ^a   Sun, Lin ^a   Yao, Zhong qiang ^a   Deng, Xiao li ^a   Liu, Rui ^a   Liu, Xiang yuan ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

AG490; JAK2 STAT3; NFATc1; Osteoclastogenesis; RANKL

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN C FOS; PROTEIN KINASE B; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SERINE; SMALL INTERFERING RNA; STAT3 PROTEIN; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; BONE DISEASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG INHIBITION; FLOW CYTOMETRY; GENE EXPRESSION; IN VITRO STUDY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; CELL DIFFERENTIATION; CELL LINE; GENE EXPRESSION; MACROPHAGES; MICE; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; RANK LIGAND; STAT3 TRANSCRIPTION FACTOR; TYRPHOSTINS;

MURINAE;

EID: 84878996683     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.04.084     Document Type: Article

References (25)

1. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
2. Hirayama T., Danks L., Sabokbar A., Athanasou N.A. Osteoclast formation and activity in the pathogenesis of osteoporosis in rheumatoid arthritis. Rheumatology (Oxford) 2002, 41:1232-1239.
3. Quinn J.M., Gillespie M.T. Modulation of osteoclast formation. Biochem. Biophys. Res. Commun. 2005, 328:739-745.
4. Walsh M.C., Kim N., Kadono Y., Rho J., Lee S.Y., Lorenzo J., Choi Y. Osteoimmunology: interplay between the immune system and bone metabolism. Annu. Rev. Immunol. 2006, 24:33-63.
5. Hsu H., Lacey D.L., Dunstan C.R., Solovyev I., Colombero A., Timms E., Tan H.L., Elliott G., Kelley M.J., Sarosi I., Wang L., Xia X.Z., Elliott R., Chiu L., Black T., Scully S., Capparelli C., Morony S., Shimamoto G., Bass M.B., Boyle W.J. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 1999, 96:3540-3545.
6. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., Boyle W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
7. Hirotani H., Tuohy N.A., Woo J.T., Stern P.H., Clipstone N.A. The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells. J. Biol. Chem. 2004, 279:13984-13992.
8. Bezbradica J.S., Medzhitov R. Integration of cytokine and heterologous receptor signaling pathways. Nat. Immunol. 2009, 10:333-339.
9. Ghoreschi K., Laurence A., O'Shea J.J. Janus kinases in immune cell signaling. Immunol. Rev. 2009, 228:273-287.
10. Levy D.E., Darnell J.E. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 2002, 3:651-662.
11. Fuke H., Shiraki K., Sugimoto K., Tanaka J., Beppu T., Yoneda K., Yamamoto N., Ito K., Masuya M., Takei Y. Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 2007, 363:738-744.
12. Quintas-Cardama A., Kantarjian H., Cortes J., Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat. Rev. Drug Discovery 2011, 10:127-140.
13. Flanagan M.E., Blumenkopf T.A., Brissette W.H., Brown M.F., Casavant J.M., Shang-Poa C., Doty J.L., Elliott E.A., Fisher M.B., Hines M., Kent C., Kudlacz E.M., Lillie B.M., Magnuson K.S., McCurdy S.P., Munchhof M.J., Perry B.D., Sawyer P.S., Strelevitz T.J., Subramanyam C., Sun J., Whipple D.A., Changelian P.S. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J. Med. Chem. 2010, 53:8468-8484.
14. Tanaka Y., Suzuki M., Nakamura H., Toyoizumi S., Zwillich S.H. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res. 2011, 63:1150-1158.
15. Duhe R.J., Clark E.A., Farrar W.L. Characterization of the in vitro kinase activity of a partially purified soluble GST/JAK2 fusion protein. Mol. Cell. Biochem. 2002, 236:23-35.
16. Luo C., Laaja P. Inhibitors of JAKs/STATs and the kinases: a possible new cluster of drugs. Drug Discovery Today 2004, 9:268-275.
17. Kwak H.B., Kim H.S., Lee M.S., Kim K.J., Choi E.Y., Choi M.K., Kim J.J., Cho H.J., Kim J.W., Bae J.M., Kim Y.K., Park B.H., Ha H., Chun C.H., Oh J. Pyridone 6, a pan-Janus-activated kinase inhibitor, suppresses osteoclast formation and bone resorption through down-regulation of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand (RANKL)-induced c-Fos and nuclear factor of activated T cells (NFAT) c1 expression. Biol. Pharm. Bull. 2009, 32:45-50.
18. Li C., Zhao J., Sun L., Yao Z., Liu R., Huang J., Liu X. RANKL downregulates cell surface CXCR6 expression through JAK2/STAT3 signaling pathway during osteoclastogenesis. Biochem. Biophys. Res. Commun. 2012, 429:156-162.
19. Bittorf T., Jaster R., Ludtke B., Kamper B., Brock J. Requirement for JAK2 in erythropoietin-induced signalling pathways. Cell Signal. 1997, 9:85-89.
20. O'Shea J.J., Holland S.M., Staudt L.M. JAKs and STATs in immunity, immunodeficiency, and cancer. N. Engl. J. Med. 2013, 368:161-170.
21. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 2007, 7:292-304.
22. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., Saiura A., Isobe M., Yokochi T., Inoue J., Wagner E.F., Mak T.W., Kodama T., Taniguchi T. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 2002, 3:889-901.
23. Matsuo K., Galson D.L., Zhao C., Peng L., Laplace C., Wang K.Z., Bachler M.A., Amano H., Aburatani H., Ishikawa H., Wagner E.F. Nuclear factor of activated T cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J. Biol. Chem. 2004, 279:26475-26480.
24. Miyazaki T., Katagiri H., Kanegae Y., Takayanagi H., Sawada Y., Yamamoto A., Pando M.P., Asano T., Verma I.M., Oda H., Nakamura K., Tanaka S. Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J. Cell Biol. 2000, 148:333-342.
25. Liu H., Ma Y., Cole S.M., Zander C., Chen K.H., Karras J., Pope R.M. Serine phosphorylation of STAT3 is essential for Mcl-1 expression and macrophage survival. Blood 2003, 102:344-352.